Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Consolidated Net Income: 2022-2025

Historic Consolidated Net Income for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$892,300.

  • Addex Therapeutics' Consolidated Net Income rose 65.69% to -$892,300 in Q2 2025 from the same period last year, while for Jun 2025 it was -$1.6 million, marking a year-over-year increase of 79.94%. This contributed to the annual value of $13.6 million for FY2024, which is 251.63% up from last year.
  • Addex Therapeutics' Consolidated Net Income amounted to -$892,300 in Q2 2025, which was down 36.64% from -$653,016 recorded in Q1 2025.
  • Addex Therapeutics' 5-year Consolidated Net Income high stood at $6.6 million for Q4 2022, and its period low was -$7.5 million during Q2 2022.
  • For the 3-year period, Addex Therapeutics' Consolidated Net Income averaged around -$1.2 million, with its median value being -$867,290 (2024).
  • As far as peak fluctuations go, Addex Therapeutics' Consolidated Net Income tumbled by 133.51% in 2023, and later skyrocketed by 99.87% in 2024.
  • Over the past 4 years, Addex Therapeutics' Consolidated Net Income (Quarterly) stood at $6.6 million in 2022, then slumped by 133.51% to -$2.2 million in 2023, then spiked by 99.18% to -$18,156 in 2024, then soared by 65.69% to -$892,300 in 2025.
  • Its Consolidated Net Income was -$892,300 in Q2 2025, compared to -$653,016 in Q1 2025 and -$18,156 in Q4 2024.